Olema Pharmaceuticals (OLMA) Other Non Operating Income (2020 - 2026)
Olema Pharmaceuticals' (OLMA) quarterly Other Non Operating Income came in at $121000.0 in Q1 2026, up 402.5% year-on-year from $24079.6 in Q1 2025, and up 830.77% on a QoQ basis from $13000.0 in Q4 2025.
Olema Pharmaceuticals (OLMA) Other Non Operating Income (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Other Non Operating Income data on file, last reported at $121000.0 in Q1 2026.
- On a quarterly basis, Other Non Operating Income rose 402.5% year-over-year to $121000.0 in Q1 2026; TTM through Mar 2026 was $184000.0, a 308.89% increase from a year earlier, with the FY2025 full-year figure at $23000.0, down 77.45% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $121000.0, up from $13000.0 in the prior quarter.
- Over the last five years, Other Non Operating Income for OLMA reached as high as $138000.0 in Q3 2024 and fell as low as -$120000.0 in Q3 2022.
- Historically, Other Non Operating Income has averaged $11764.7 across 5 years, with a median of $13000.0 in 2025.
- Across the five-year window, Other Non Operating Income soared 2100.0% in 2022 and tumbled 335.29% in 2025, its largest moves.
- Year by year, Other Non Operating Income stood at $67000.0 in 2022, then jumped by 38.81% to $93000.0 in 2023, then slumped by 200.0% to -$93000.0 in 2024, then surged by 113.98% to $13000.0 in 2025, then surged by 830.77% to $121000.0 in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were $121000.0 in Q1 2026, $13000.0 in Q4 2025, and $12000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Olema Pharmaceuticals | 1.21 Bn | 1.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 38,000.00 |
| Mar 31, 2025 | -40,000.00 |
| Dec 31, 2024 | -93,000.00 |
| Sep 30, 2024 | 138,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 93,000.00 |
| Sep 30, 2023 | -79,000.00 |
| Jun 30, 2023 | -44,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 67,000.00 |
| Sep 30, 2022 | -120,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 10,000.00 |
| Sep 30, 2021 | -56,000.00 |
| Jun 30, 2021 | -1,000.00 |